Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

Published by

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR, IR, IR, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Promotion, Marketing, Marketing, Marketing, Marketing

May 21, 2020

 
 
 

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

  •  Sub-distributor has a network of state and local government clients seeking testing solutions
  •  Return to Church program being initiated in Orlando, Fla. area

Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced its first commercial sale of COVID-19 tests.  The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs. Todos’ sub-distributor’s first sale was for rapid IgM/IgG fingerprick antibody test kits that will be deployed over Memorial Day weekend for the first of several Return to Church programs being planned. Todos’ sub-distributor’s church network covers over 84,000 Christian church congregations reaching over 28 million Americans. 

“This sub-distribution agreement gives Todos’ U.S. distribution division access to a network of state and local governments, as well as Christian churches, and other communities of faith, that are for the first time pursuing COVID-19 testing services as they seek to responsibly reopen their congregations,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We provide organizations and their lab partners with access to a comprehensive, steady supply of bundled, high-quality, FDA-compliant PCR, and antibody testing solutions that address their needs as they implement COVID-19 testing programs. As private organizations begin to take control of their COVID-19 testing, Todos plans to be a solutions provider for both organizations and labs seeking to more efficiently administer COVID testing in the United States.”

 
 
 
 

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.

Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.

Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2  & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc.  (OTC: EMOR), to support the commercialization of its COVID-19 testing paradigm.


Articles authored by Martin Signer

Published: Oct 21, 2020

Published: Sep 2, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 23, 2020

Published: Aug 6, 2020

Published: Aug 6, 2020

Published: Aug 4, 2020

Published: Jul 3, 2020

Published: Jun 27, 2020

Published: Jun 11, 2020

Published: Jun 9, 2020

Published: Jun 4, 2020

Published: May 17, 2020

Published: May 12, 2020

Published: May 11, 2020

Published: May 6, 2020

Published: Apr 27, 2020

Published: Apr 26, 2020

Published: Apr 15, 2020

Published: Apr 6, 2020

Published: Mar 24, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 18, 2020

Published: Mar 9, 2020

Published: Mar 6, 2020

Published: Mar 4, 2020

Published: Mar 2, 2020

Published: Feb 24, 2020

Published: Feb 18, 2020

Published: Feb 11, 2020

Published: Feb 9, 2020

Published: Jan 17, 2020

Published: Jan 7, 2020

Published: Jan 3, 2020

Published: Dec 25, 2019

Published: Dec 18, 2019

Published: Nov 26, 2019

Published: Nov 6, 2019

Published: Oct 20, 2019

Published: Oct 12, 2019

Published: Oct 11, 2019

Published: Oct 3, 2019

Published: Oct 2, 2019

Published: Oct 1, 2019

Published: Sep 29, 2019

Published: Sep 29, 2019

Published: Sep 19, 2019

Published: Sep 16, 2019

Published: Sep 14, 2019

Published: Sep 5, 2019

Published: Sep 3, 2019

Published: Aug 30, 2019

Published: Aug 29, 2019

Published: Aug 15, 2019

Published: Jul 21, 2019

Published: Jul 8, 2019

Published: Jun 29, 2019

Published: Jun 11, 2019

Published: May 22, 2019

Published: May 5, 2019

Published: Apr 21, 2019

Published: Apr 19, 2019

Published: Mar 28, 2019

Published: Mar 16, 2019

Published: Mar 16, 2019

Published: Mar 6, 2019

Published: Feb 25, 2019

Published: Feb 24, 2019

Published: Feb 7, 2019

Published: Apr 20, 2018

Published: Feb 18, 2018

Published: Feb 7, 2018